Elitra announces issuance of patent on genome-wide shotgun antisense method.
"The issuance of this patent covering one of our ultra-rapid gene discovery technologies solidifies our competitive position in antimicrobial functional genomics," said Harry F. Hixson, Elitra's Chairman and Chief Executive Officer." In addition, we have now filed patent applications on a majority of the antimicrobial targets which we believe to be important for novel antimicrobial drug discovery. While we intend to continue to discover additional drug targets, we plan to move as many targets as possible into high throughput drug discovery screening programs using our proprietary cell-based assays, either alone or through corporate collaborations."
Elitra is a leader in antimicrobial functional genomics and is focused on the identification, development and commercialization of novel antimicrobial compounds that target essential gene products of pathogenic organisms. Elitra's ultra-rapid gene-to-lead approach allows it to rapidly proceed from analyzing the genes of bacteria and fungi to testing for effective drug candidates.
|Printer friendly Cite/link Email Feedback|
|Comment:||Elitra announces issuance of patent on genome-wide shotgun antisense method.|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||May 1, 2001|
|Previous Article:||Acambis receives broad patent for passive vaccination against C. difficile.|
|Next Article:||Vical obtains angiogenesis patent.|